. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . aggregated data generated by national registries, clinics or professional socie- ties have been collected, analyzed by the European IVF-monitoring Consortium (EIM) and reported in 23 manuscripts published in Human Reproduction and Human Reproduction Open. Study design, size, duration: Yearly collection of European medically assis- ted reproduction (MAR) data by EIM for ESHRE. The data on treatments performed between January 1 and December 31 2020 in 35 European coun- tries were provided by either National Registries or registries based on personal initiatives of medical associations and scientific organizations. Participants/materials, setting, methods: In all, 1157 clinics offering ART services in 35 countries reported a total of 713 708 treatment cycles, in- volving 110 097 with IVF, 253 095 with ICSI, 239 759 with frozen embryo replacement (FET), 46 610 with preimplantation genetic testing (PGT), 59 906 with egg donation (ED), 344 with IVM of oocytes and 3897 cycles with frozen oocyte replacement (FOR). European data on IUI using husband/part- ner’s semen (IUI-H) and donor semen (IUI-D) were reported from 1176 institutions offering IUI in 28 and 18 countries, respectively. A total of 102 702 treatments with IUI-H and 36 476 treatments with IUI-D were included. A total of 18 270 fertility preservation (FP) interventions from 15 countries in- cluding oocyte, ovarian tissue, semen and testicular tissue banking in pre-and post-pubertal patients were reported. Main results and the role of chance: In total, 1157 IVF clinics participated (88.5% of registered clinics in the participating countries). Next to these also 1176 IUI units reported their data. In the 35 reporting countries, after IVF the clinical pregnancy rates (PR) per aspiration and per transfer in 2020 were sim- ilar to those observed in 2019 (27.9% and 32.9% versus 28.5% and 34.6%, respectively). After ICSI the corresponding rates were also similar to those achieved in 2019 (24.3% en 32.2% versus 26.2% and 33.5%). After FET with own embryos, the PR per thawing is stabilizing, 35.1% in 2019 and 34.6% in 2020. After ED the PR per fresh embryo transfer was 50.4% (50.5% in 2019) and per FOR 45.3% (44.8% in 2019). In IVF and ICSI together, the trend to- wards the transfer of fewer embryos continues with the transfer of 1, 2, 3 and 4 embryos in 62.1%, 32.3%, 2.2% and 0.3% of all treatments, respec- tively (corresponding to 55.4%, 39.9%, 2.6% and 0.2% in 2019). This resulted in a proportion of singleton, twin and triplet DRs of 90.5%, 9.3% and 0.2%, respectively (compared to 87.7%, 12.0% and 0.3%, respectively in 2019). Treatments with FER in 2020 resulted in twin and triplet DR of 7.0% and 0.1%, respectively (versus 9.3% and 0.1% in 2019). After IUI, the DRs remained similar at 8.9% after IUI-H (9.2% in 2019) and at 12.4% after IUI-D (12.1% in 2019). Twin and triplet DRs after IUI-H were 8.3% and 0.4%, re- spectively (in 2019: 8.7% and 0.3%) and 5.8% and 0.2% after IUI-D (in 2019: 6.2% and 0.2%). The majority of FP interventions included the cryopreserva- tion of oocytes (n ¼ 5 365 from 14 countries) and of ejaculated sperm (n ¼ 11 571 from 14 countries). Limitations, reasons for caution: As the methods of data collection and levels of completeness of reported data vary among European countries, the results should be interpreted with caution. For this abstract, some countries were not able to provide adequate data about the number of centers and ini- tiated cycles and deliveries. WIDER IMPLICATIONS OF THE FINDINGS: The 24rd ESHRE report on ART and IUI shows a continuous increase of reported treatment numbers and MAR-derived live births in Europe. Being al- ready the largest data collection on MAR in Europe, continuous efforts to stimulate data collection and reporting strive for future quality control and completeness of the data and offer higher transparency and vigilance in the field of reproductive medicine. Trial registration number: XXXX Abstract citation ID: dead093.187 O-154 ICMART preliminary world report 2019 G.D. Adamson 1 , S. Dyer 2 , F. Zegers-Hochschild 3 , G. Chambers 4 , J. De Mouzon 5 , O. Ishihara 6 , M. Kupka 7 , V. Baker 8 , M. Banker 9 , E. Elgindy 10 , F. Bai 11 , S.C. Jwa 12 1 Equal3 Fertility, Reproductive Endocrinology and Infertility, Cupertino, U.S.A. 2 Groote Schuur Hospital and University of Cape Town., Obstetrics and Gynaecology, Cape Town, South Africa 3 Universidad Diego Portales, Program of Ethics and Public Policies in Human Reproduction, Santiago, Chile 4 University of New South Wales, National Perinatal Epidemiology and Statistics Unit NPESU, Sydney, Australia 5 French Institute of Health and Medical Research, Inserm, Paris, France 6 Kagawa Nutrition University, Department of Obstetrics and Gynaecology, Saitama, Japan 7 Ludwig-Maximilian University, Fertility Center – Gynaekologicum- Hamburg, Hamburg, Germany 8 Johns Hopkins University School of Medicine, Division of Reproductive Endocrinology and Infertility, Baltimore, U.S.A. 9 Nova IVI Fertility, Reproductive Medicine, Ahmedabad, India 10 Zagazig University, Obstetrics and Gynecology, Zagazig, Egypt 11 National Center for Women and Children’s Health- China CDC, ART Management Department, Beijing, China 12 Saitama Medical University, Obstetrics and Gynecology, Saitama, Japan Abstract title: International Committee for Monitoring Assisted Reproductive Technologies (ICMART) Preliminary World Report on ART, 2019 Study question: In 2019 what was the global utilization, effectiveness and safety of ART? Summary answer: Globally, ART utilization and data collection continue to in- crease but with wide variations in utilization, effectiveness and safety. What is known already: ICMART began ART global data collection in 1991. Utilization, effectiveness and safety have continuously improved with more cycles, higher pregnancy rates and lower multiple birth rates, the latter due to the transfer of fewer embryos. Frozen embryo transfer (FET) and do- nor egg cycles continue to increase. However, wide variations in practice and outcomes exist globally. Approximately 10 million ART babies have been born. ICMART has helped develop registries internationally. A new electronic data collection platform has been developed with the University of New South Wales (UNSW) in Sydney, Australia; nevertheless, data collection and quality remain challenging. Study design, size, duration: Countries and regions annually collect ART data, some prospectively and others retrospectively. ICMART retrospectively requested data from all known global sources for 2019 and reviewed them for missing or incorrect data. The dataset was reviewed and corrected by ICMART, in partnership with UNSW for validation and analysis, then ICMART finalized the results tables. Standardized definitions from The International Glossary on Infertility and Fertility Care, 2017, and previously developed methods were used. Preliminary results are presented. Participants/materials, setting, methods: The European IVF Monitoring Consortium (EIM), Latin American Network of Assisted Reproduction (REDLARA), Australian/ New Zealand Registry and African Network and Registry for ART (ANARA) submitted regional data, and other countries con- tributed national data, through standardized formats, to ICMART. A few individual clinics with no registry access also contributed. Data received were reviewed, corrected, and validated to the extent possible, analyzed and sum- marized by ICMART using descriptive statistics. Main results and the role of chance: Data collection and analysis are on- going, so the presented results are preliminary. The number of ART cycles continues to increase, but utilization is still highly variable among countries and regions. Regional and country differences persist in the age of women treated, number of embryos transferred, live birth rates, rate of multiple births, use of ICSI, cryopreservation cycles and other factors. The role of chance is minimal. Actual global ART results are limited to reporting countries and clinics representing 90 to 95% of global cycles. However, this is a very large sample size from which imputation of total global results is performed. Limitations, reasons for caution: Most, but not all, countries report to ICMART. Some countries have limited data and many countries have limited data validation. ICMART can perform only minimal verification of submitted data. Widespread adherence to consensus definitions provided in the Glossary takes time and requires translation into multiple languages. Standardization of validation and reporting is an ongoing process because of missing data and continuing changes in clinical practice. Wider implications of the findings: ICMART World Reports standardize data, track trends, enable comparisons, stimulate questions and improve ART i96 39 th Hybrid Annual Meeting of the ESHRE, Copenhagen – Denmark, 25-28 June 2023 Downloaded from https://academic.oup.com/humrep/article/38/Supplement_1/dead093.187/7203162 by guest on 24 June 2023